Kingworld Medicines Group Ltd.

As of December 31, 2025, Kingworld Medicines Group Ltd. carries a market capitalization of 308.08M, placing it among publicly traded companies globally. Its enterprise value stands at 564.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Kingworld Medicines Group Ltd. has 592.46M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Kingworld Medicines Group Ltd. maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Kingworld Medicines Group Ltd.'s stock has declined approximately 25.00% over the past 52 weeks. The 50-day moving average sits at 0.40, while the 200-day moving average is 0.45.

As of December 31, 2025, Kingworld Medicines Group Ltd. holds 305.58M in cash and equivalents against 482.85M in total debt, resulting in a net debt position of 166.91M. Total book value stands at 687.43M, with working capital of 53.91M providing operational flexibility.